Approval · Notice of Compliance 25616 · 2021
REVOLADE: Notice of Compliance 25616
Issued April 8, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25616
- Date
- April 8, 2021
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of alternate sites for drug substance and drug produit
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REVOLADE | Not yet assigned | — |
Medicinal ingredients
- ELTROMBOPAG OLAMINE 25 MG per TAB
- ELTROMBOPAG OLAMINE 50 MG per TAB